|
1
|
Yang JD and Roberts LR: Hepatocellular
carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ascha MS, Hanouneh IA, Lopez R, Tamimi TA,
Feldstein AF and Zein NN: The incidence and risk factors of
hepatocellular carcinoma in patients with nonalcoholic
steatohepatitis. Hepatology. 51:1972–1978. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rahbari NN, Mehrabi A, Mollberg NM, et al:
Hepatocellular carcinoma: current management and perspectives for
the future. Ann Surg. 253:453–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinomaincidence, mortality and survival trends in
the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: an update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yeh SH and Chen PJ: Gender disparity of
hepatocellular carcinoma: the roles of sex hormones. Oncology.
78(Suppl 1): 172–179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ruggieri A, Barbati C and Malorni W:
Cellular and molecular mechanisms involved in hepatocellular
carcinoma gender disparity. Int J Cancer. 127:499–504. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gelmann EP: Molecular biology of the
androgen receptor. J Clin Oncol. 20:3001–3015. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Simental JA, Sar M, Lane MV, French FS and
Wilson EM: Transcriptional activation and nuclear targeting signals
of the human androgen receptor. J Biol Chem. 266:510–518.
1991.PubMed/NCBI
|
|
11
|
Zegarra-Moro OL, Schmidt LJ, Huang H and
Tindall DJ: Disruption of androgen receptor function inhibits
proliferation of androgen-refractory prostate cancer cells. Cancer
Res. 62:1008–1013. 2002.PubMed/NCBI
|
|
12
|
Truica CI, Byers S and Gelmann EP:
Beta-catenin affects androgen receptor transcriptional activity and
ligand specificity. Cancer Res. 60:4709–4713. 2000.PubMed/NCBI
|
|
13
|
Yeh S, Lin HK, Kang HY, Thin TH, Lin MF
and Chang C: From HER2/Neu signal cascade to androgen receptor and
its coactivators: a novel pathway by induction of androgen target
genes through MAP kinase in prostate cancer cells. In: Proc Natl
Acad Sci USA. 96. pp. 5458–5463. 1999; View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nie H, Cao Q, Zhu L, Gong Y, Gu J and He
Z: Acetylcholine acts on androgen receptor to promote the migration
and invasion but inhibit the apoptosis of human hepatocarcinoma.
PLoS One. 8:e616782013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barone M, Margiotta M, Scavo MP, et al:
Possible involvement of androgen receptor alterations in
hepatocarcinogenesis. Dig Liver Dis. 41:665–670. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kalra M, Mayes J, Assefa S, Kaul AK and
Kaul R: Role of sex steroid receptors in pathobiology of
hepatocellular carcinoma. World J Gastroenterol. 14:5945–5961.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Villa E: Androgen receptor alterations in
hepatocarcinogenesis. Dig Liver Dis. 41:632–633. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng H, Cheng AS, Tsang DP, et al: Cell
cycle-related kinase is a direct androgen receptor-regulated gene
that drives β-catenin/T cell factor-dependent hepatocarcinogenesis.
J Clin Invest. 121:3159–3175. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zender L and Kubicka S: Androgen receptor
and hepatocarcinogenesis: what do we learn from HCC mouse models?
Gastroenterology. 135:738–740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma WL, Hsu CL, Wu MH, et al: Androgen
receptor is a new potential therapeutic target for the treatment of
hepatocellular carcinoma. Gastroenterology. 135:947–955. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ao J, Meng J, Zhu L, et al: Activation of
androgen receptor induces ID1 and promotes hepatocellular carcinoma
cell migration and invasion. Mol Oncol. 6:507–515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma WL, Hsu CL, Yeh CC, et al: Hepatic
androgen receptor suppresses hepatocellular carcinoma metastasis
through modulation of cell migration and anoikis. Hepatology.
56:176–185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vizoso FJ, Rodriguez M, Altadill A, et al:
Liver expression of steroid hormones and Apolipoprotein D receptors
in hepatocellular carcinoma. World J Gastroenterol. 13:3221–3227.
2007.PubMed/NCBI
|
|
24
|
Tavian D, De Petro G, Pitozzi A, Portolani
N, Giulini SM and Barlati S: Androgen receptor mRNA
under-expression in poorly differentiated human hepatocellular
carcinoma. Histol Histopathol. 17:1113–1119. 2002.PubMed/NCBI
|
|
25
|
Chen PJ, Yeh SH, Liu WH, et al: Androgen
pathway stimulates microRNA-216a transcription to suppress the
tumor suppressor in lung cancer-1 gene in early
hepatocarcinogenesis. Hepatology. 56:632–643. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu R, Zhang JS, Zhu YZ, et al:
HBx-induced androgen receptor expression in HBV-associated
hepatocarcinoma is independent of the methylation status of its
promoter. Histol Histopathol. 26:23–35. 2011.PubMed/NCBI
|
|
27
|
Dahmani R, Just PA and Perret C: The
Wnt/β-catenin pathway as a therapeutic target in human
hepatocellular carcinoma. Clin Res Hepatol Gastroenterol.
35:709–713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee JM, Yang J, Newell P, et al: β-Catenin
signaling in hepatocellular cancer: Implications in inflammation,
fibrosis, and proliferation. Cancer Lett. 343:90–97. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nault JC and Zucman-Rossi J: Genetics of
hepatobiliary carcinogenesis. Semin Liver Dis. 31:173–187. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee E, Madar A, David G, Garabedian MJ,
Dasgupta R and Logan SK: Inhibition of androgen receptor and
β-catenin activity in prostate cancer. In: Proc Natl Acad Sci USA.
110. pp. 15710–15715. 2013; View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Y, Zheng Y, Izumi K, et al: Androgen
activates β-catenin signaling in bladder cancer cells. Endocr Relat
Cancer. 20:293–304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tian Y, Wan H and Tan G: Cell
cycle-related kinase in carcinogenesis. Oncol Lett. 4:601–606.
2012.PubMed/NCBI
|
|
33
|
Takahashi K, Yan I, Wen HJ and Patel T:
microRNAs in liver disease: from diagnostics to therapeutics. Clin
Biochem. 46:946–952. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gailhouste L and Ochiya T: Cancer-related
microRNAs and their role as tumor suppressors and oncogenes in
hepatocellular carcinoma. Histol Histopathol. 28:437–451.
2013.PubMed/NCBI
|
|
35
|
Guo J and Friedman SL: The expression
patterns and clinical significance of microRNAs in liver diseases
and hepatocellular carcinoma. Curr Pharm Des. 19:1262–1272. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liang QL, Chen GQ, Li ZY and Wang BR:
Function and histopathology of a cell adhesion molecule TSLC1 in
cancer. Cancer Invest. 29:107–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang J, Ning J, Geng J, Cui B and Dong X:
Down-regulation of tumor suppressor in lung cancer 1 (TSLC1)
expression correlates with poor prognosis in patients with colon
cancer. J Mol Histol. 43:715–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chiu CM, Yeh SH, Chen PJ, et al: Hepatitis
B virus X protein enhances androgen receptor-responsive gene
expression depending on androgen level. In: Proc Natl Acad Sci USA.
104. pp. 2571–2578. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zheng Y, Chen WL, Ma WL, Chang C and Ou
JH: Enhancement of gene transactivation activity of androgen
receptor by hepatitis B virus X protein. Virology. 363:454–461.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lok AS and McMahon BJ: Chronic hepatitis
B: update 2009. Hepatology. 50:661–662. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu C, Zhou W, Wang Y and Qiao L: Hepatitis
B virus-induced hepatocellular carcinoma. Cancer Lett. 345:216–222.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bharadwaj M, Roy G, Dutta K, Misbah M,
Husain M and Hussain S: Tackling hepatitis B virus-associated
hepatocellular carcinoma - the future is now. Cancer Metastasis
Rev. 32:229–268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pollicino T, Saitta C and Raimondo G:
Hepatocellular carcinoma: the point of view of the hepatitis B
virus. Carcinogenesis. 32:1122–1132. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Giacomin A, Cazzagon N, Sergio A, Vanin V
and Farinati F: Hepatitis B virus-related hepatocellular carcinoma:
primary, secondary, and tertiary prevention. Eur J Cancer Prev.
20:381–388. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tian Y, Kuo CF, Chen WL and Ou JH:
Enhancement of hepatitis B virus replication by androgen and its
receptor in mice. J Virol. 86:1904–1910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu MH, Ma WL, Hsu CL, et al: Androgen
receptor promotes hepatitis B virus-induced hepatocarcinogenesis
through modulation of hepatitis B virus RNA transcription. Sci
Transl Med. 2:32ra352010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xia L, Huang W, Tian D, et al: Forkhead
box Q1 promotes hepatocellular carcinoma metastasis by
transactivating ZEB2 and VersicanV1 expression. Hepatology.
59:958–973. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xia L, Huang W, Tian D, et al: ACP5, a
direct transcriptional target of FoxM1, promotes tumor metastasis
and indicates poor prognosis in hepatocellular carcinoma. Oncogene.
33:1395–1406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liang C, Chen W, Zhi X, et al: Serotonin
promotes the proliferation of serum-deprived hepatocellular
carcinoma cells via upregulation of FOXO3a. Mol Cancer. 12:142013.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang W, He S, Ji J, Huang J, Zhang S and
Zhang Y: The prognostic significance of FOXQ1 oncogene
overexpression in human hepatocellular carcinoma. Pathol Res Pract.
209:353–358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li Z, Tuteja G, Schug J and Kaestner KH:
Foxa1 and Foxa2 are essential for sexual dimorphism in liver
cancer. Cell. 148:72–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Su Y, Gao L, Teng L, et al: Id1 enhances
human ovarian cancer endothelial progenitor cell angiogenesis via
PI3K/Akt and NF-κB/MMP-2 signaling pathways. J Transl Med.
11:1322013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Guo Q, Guo P, Mao Q, et al: ID1 affects
the efficacy of radiotherapy in glioblastoma through inhibition of
DNA repair pathways. Med Oncol. 30:3252013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ding R, Han S, Lu Y, et al: Overexpressed
Id-1 is associated with patient prognosis and HBx expression in
hepatitis B virus-related hepatocellular carcinoma. Cancer Biol
Ther. 10:299–307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Damdinsuren B, Nagano H, Kondo M, et al:
Expression of Id proteins in human hepatocellular carcinoma:
relevance to tumor dedifferentiation. Int J Oncol. 26:319–327.
2005.PubMed/NCBI
|
|
56
|
Zhao Y, Wang X, Wang T, et al:
Acetylcholinesterase, a key prognostic predictor for hepatocellular
carcinoma, suppresses cell growth and induces chemosensitization.
Hepatology. 53:493–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Groupe d'Etude et de Traitement du
Carcinome Hépatocellulaire: Randomized trial of leuprorelin and
flutamide in male patients with hepatocellular carcinoma treated
with tamoxifen. Hepatology. 40:1361–1369. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Forbes A, Wilkinson ML, Iqbal MJ, Johnson
PJ and Williams R: Response to cyproterone acetate treatment in
primary hepatocellular carcinoma is related to fall in free 5
alpha-dihydrotestosterone. Eur J Cancer Clin Oncol. 23:1659–1664.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Iyoda K, Sasaki Y, Horimoto M, et al:
Involvement of the p38 mitogen-activated protein kinase cascade in
hepatocellular carcinoma. Cancer. 97:3017–3026. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Koul HK, Pal M and Koul S: Role of p38 MAP
kinase signal transduction in solid tumors. Genes Cancer.
4:342–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhang J, Zhang D, Wu GQ, Feng ZY and Zhu
SM: Propofol inhibits the adhesion of hepatocellular carcinoma
cells by upregulating microRNA-199a and downregulating MMP-9
expression. Hepatobiliary Pancreat Dis Int. 12:305–309. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Gao J, Ding F, Liu Q and Yao Y: Knockdown
of MACC1 expression suppressed hepatocellular carcinoma cell
migration and invasion and inhibited expression of MMP2 and MMP9.
Mol Cell Biochem. 376:21–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang M, Dai C, Zhu H, et al: Cyclophilin
A promotes human hepatocellular carcinoma cell metastasis via
regulation of MMP3 and MMP9. Mol Cell Biochem. 357:387–395. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chao Y, Chan WK, Huang YS, et al: Phase II
study of flutamide in the treatment of hepatocellular carcinoma.
Cancer. 77:635–639. 1996. View Article : Google Scholar : PubMed/NCBI
|
